Overview

A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of rituximab in combination with chemotherapy (fludarabine and cyclophosphamide) in participants with B-cell CLL.
Phase:
Phase 2
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Rituximab
Vidarabine